{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-290820","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.578764+00:00","generated_at":"2026-06-07T15:27:36.057108+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"EyePoint prices $200M public offering at $17/share to fund Phase 3 trials for EYP-1901","bullets":["Underwritten public offering of 11,764,706 shares priced at $17.00 per share; underwriters exercised option for additional 1,764,705 shares.","Expected net proceeds ~$215.9M after underwriting discounts and expenses.","Proceeds to fund two pivotal Phase 3 trials of EYP-1901 for wet AMD and other pipeline initiatives.","Closing expected December 8, 2023; J.P. Morgan, TD Cowen, Guggenheim lead underwriters.","Offering upsized from initial $175M to ~$200M gross."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-290820","json":"https://secwatch.observer/filing/0001193125-23-290820.json","markdown":"https://secwatch.observer/filing/0001193125-23-290820.md","text":"https://secwatch.observer/filing/0001193125-23-290820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/0001193125-23-290820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/d627747d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:27:36.057108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cca38542eca8acb2384aaf682724dddf289b6f1","claim":"EyePoint, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, as representative of the underwriters named therein valued at approximately $215.9 million (effective 2023-12-05).","evidence_excerpt":"On December 5, 2023, EyePoint Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten public offering (the “Offering”) of 11,764,706 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/0001193125-23-290820-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, as representative of the underwriters named therein"},{"label":"Value","value":"approximately $215.9 million"},{"label":"Effective","value":"2023-12-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}